These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11747043)

  • 21. Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
    Culyer AJ; Chalkidou K
    Value Health; 2019 Jan; 22(1):99-103. PubMed ID: 30661640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating an EQ-5D population value set: the case of Japan.
    Tsuchiya A; Ikeda S; Ikegami N; Nishimura S; Sakai I; Fukuda T; Hamashima C; Hisashige A; Tamura M
    Health Econ; 2002 Jun; 11(4):341-53. PubMed ID: 12007165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discounting, preferences, and paternalism in cost-effectiveness analysis.
    Tinghög G
    Health Care Anal; 2012 Sep; 20(3):297-318. PubMed ID: 21909720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fair approach to discounting future effects: taking a societal perspective.
    Brouwer W; van Hout B; Rutten F
    J Health Serv Res Policy; 2000 Apr; 5(2):114-8. PubMed ID: 10947546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discounting in cost-effectiveness analysis of healthcare programmes.
    Katz DA; Welch HG
    Pharmacoeconomics; 1993 Apr; 3(4):276-85. PubMed ID: 10146991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discounting in health care decision-making: time for a change?
    Sheldon TA
    J Public Health Med; 1992 Sep; 14(3):250-6. PubMed ID: 1419202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Willingness to pay methods in health care: a sceptical view.
    Cookson R
    Health Econ; 2003 Nov; 12(11):891-4. PubMed ID: 14601152
    [No Abstract]   [Full Text] [Related]  

  • 29. Valuing prevention: discounting health benefits and costs in New Zealand.
    Milne R
    N Z Med J; 2005 May; 118(1214):U1443. PubMed ID: 15886738
    [No Abstract]   [Full Text] [Related]  

  • 30. Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast.
    Cowley P
    Health Policy; 1993 May; 24(2):145-53. PubMed ID: 10128800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discounting and health benefits.
    Parsonage M; Neuburger H
    Health Econ; 1992 Apr; 1(1):71-6. PubMed ID: 1342633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-utility analysis; uncertainties restrict applicability].
    de Neeling JN
    Ned Tijdschr Geneeskd; 2004 May; 148(22):1106-10. PubMed ID: 15198066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discounting in economic evaluations: stepping forward towards optimal decision rules.
    Gravelle H; Brouwer W; Niessen L; Postma M; Rutten F
    Health Econ; 2007 Mar; 16(3):307-17. PubMed ID: 17006970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors.
    Neeser K; Szucs T; Bulliard JL; Bachmann G; Schramm W
    Value Health; 2007; 10(1):42-53. PubMed ID: 17261115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discounting in decision making: the consistency argument revisited empirically.
    Brouwer WB; van Exel NJ
    Health Policy; 2004 Feb; 67(2):187-94. PubMed ID: 14720636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.
    Cohen BJ
    Pharmacoeconomics; 2003; 21(2):75-87. PubMed ID: 12515570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Welfare economics and cost-utility analysis.
    Butler JR
    Dev Health Econ Public Policy; 1992; 1():143-57. PubMed ID: 10151743
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.
    Aggarwal R; Ghoshal UC; Naik SR
    J Hepatol; 2003 Feb; 38(2):215-22. PubMed ID: 12547411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.